https://www.selleckchem.com/products/gdc-0068.html
Publication of real world data on the results of treatment with (approved) drugs is important to allow for a reasonable judgement about the efficacy of a medication, especially since due to the nature of controlled clinical studies certain patient groups, who in daily clinical routine would best benefit from such new treatments, are excluded from study inclusions. In the present review, real-world data on the treatment of hidradenitis suppurativa (HS) are summarized. It appears that adalimumab, as the only approved biological treatment